Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a ...
Zacks Research cut their Q4 2026 earnings per share (EPS) estimates for shares of Ubiquiti in a report issued on Wednesday, ...
Opinion
4dOpinion
Zacks Investment Research on MSNTop Research Reports for Bank of America, Accenture & ServiceNowThe Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Bank of America Corp. (BAC), ...
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research ...
A recent ransomeware attack targeted Zacks, an American investment firm, and a cybercriminal claimed to have stolen records ...
(TSQ) on Monday reported earnings of $24.6 million in its fourth quarter. The Purchase, New York-based company said it had net ...
12d
Zacks.com on MSNWhy ACM Research (ACMR) Might be Well Poised for a SurgeACM Research (ACMR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $15 million in its fourth quarter. The San Diego-based company said it had a loss of 18 cents per share.
ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Regenxbio Inc. (RGNX) on Thursday reported a loss of $51.2 million in its fourth quarter. On a per-share basis, the Rockville, Maryland-based company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results